Key Points
- Use the highest‑yield diagnostic test early; do not let testing delay time‑critical therapy.
- Set objective targets (hemodynamic, neurologic, respiratory) and reassess frequently.
- Plan definitive source control or immunomodulation when indicated; document follow‑up and patient education.
Algorithm
- Stop suspected culprit drugs immediately; list all non‑essential meds.
- Admit to burn/ICU; calculate SCORTEN; begin aggressive wound and fluid management.
- Initiate early enteral nutrition and pain control; strict infection surveillance.
- Consider cyclosporine or etanercept in experienced centers; discuss IVIG on case basis.
- Plan ophthalmology/urogenital care to prevent sequelae; arrange rehab and dermatology follow‑up.
Clinical Synopsis & Reasoning
Life‑threatening epidermal necrosis usually triggered by medications. Stop culprit drug, admit to burn/ICU, apply SCORTEN for prognosis, and provide meticulous wound, fluid, and infection care. Consider cyclosporine or etanercept in selected cases; IVIG evidence mixed.
Treatment Strategy & Disposition
Stabilize ABCs. Initiate guideline‑concordant first‑line therapy with precise dosing and continuous monitoring. Escalate to advanced or procedural interventions based on explicit failure criteria. Define ICU, step‑down, and ward disposition triggers; involve specialty teams early.
Epidemiology / Risk Factors
- Risk varies by comorbidity and precipitants; see citations for condition‑specific data.
Investigations
| Test | Role / Rationale | Typical Findings | Notes |
|---|---|---|---|
| Medication history 1–3 weeks prior | Etiology | High‑risk drugs (e.g., sulfonamides, allopurinol, anticonvulsants) | Identify culprit |
| SCORTEN variables | Prognosis | Age, TBSA, malignancy, HR, BUN, bicarb, glucose | Calculate on day 1 and 3 |
| Cultures only if infected | Infection control | Secondary sepsis risk | Avoid routine prophylactic antibiotics |
Pharmacology
| Medication/Intervention | Mechanism | Onset | Role in Therapy | Limitations |
|---|---|---|---|---|
| Cyclosporine 3–5 mg/kg/day | Immunomodulator | Days | May reduce mortality/time to re‑epithelialization | Monitor renal/BP |
| Etanercept 50 mg SC once (± repeat) | TNF‑α inhibitor | Days | Emerging evidence for benefit | Infection risk |
| IVIG 2 g/kg total (variable) | Immunotherapy | Days | Mixed evidence | Volume load, cost |
| Supportive burn‑style care | Protocolized | Immediate | Core of therapy | Fluids, temperature, nutrition, wound care |
Prognosis / Complications
- Outcome depends on timeliness of diagnosis and definitive therapy; monitor for complications.
Patient Education / Counseling
- Provide red‑flag education, adherence guidance, and explicit return precautions; arrange timely specialty follow‑up.
References
- British Association of Dermatologists Guidelines for SJS/TEN (2016) — Link
- Lancet Review on SJS/TEN (2021) — Link
Meet MDSteps: Smarter USMLE® Prep
MDSteps streamlines your study with an adaptive QBank (19,000+ high-yield MCQs across all 3 Steps), full CCS case simulations for Step 3 with live vitals and timed orders, and an exam-readiness dashboard that turns practice into insight. Build mastery by system and discipline, auto-create missed-item decks (Anki-exportable), and keep momentum with pacing guidance, trend lines, and suggested next sessions—so every block moves you closer to test-day confidence.
Compared with staples like UWorld and AMBOSS, MDSteps aims to give you the best of both worlds: exam-style practice that adapts to you, plus real-time analytics and a full CCS runner—all in one place. If you want targeted, exam-relevant reps with feedback that actually changes how you study, MDSteps is built for you.
Eplore MDSteps